Galectin therapeutics inc (GALT)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Operating expenses:
Research and development

8,965

7,467

4,863

4,865

4,819

6,471

6,281

8,279

10,247

11,721

14,152

13,938

14,720

15,325

14,806

15,981

14,355

13,114

12,280

9,795

8,789

8,425

7,740

6,953

6,708

5,688

5,295

5,512

5,378

4,527

4,387

3,633

3,709

3,552

3,003

2,582

0

0

0

General and administrative

5,690

5,971

6,372

6,187

6,972

7,131

6,709

6,445

5,232

4,526

4,321

4,658

4,893

6,156

6,759

6,946

7,698

6,965

6,850

6,913

6,637

7,005

6,760

7,615

7,032

6,416

6,387

5,521

5,776

5,372

6,502

6,393

6,640

6,857

5,246

4,984

0

0

0

Total operating expenses

14,655

13,438

11,235

11,052

11,791

13,602

12,990

14,724

15,479

16,247

18,473

18,596

19,613

21,481

21,565

22,927

22,053

20,079

19,130

16,708

15,426

15,430

14,500

14,568

13,740

12,104

11,682

11,033

11,154

9,899

10,889

10,026

10,349

10,409

8,249

7,566

0

0

0

Total operating loss

-14,655

-13,438

-11,235

-11,052

-11,791

-13,602

-12,990

-14,724

-15,479

-16,247

-18,473

-18,596

-19,613

-21,481

-21,565

-22,927

-22,053

-20,079

-19,130

-16,708

-15,426

-15,430

-14,500

-14,568

-13,740

-12,104

-11,682

-11,033

-11,154

-9,899

-10,889

-10,026

-10,349

-10,409

-8,249

-7,566

0

0

0

Other income (expense):
Interest income

267

231

173

87

48

38

26

17

19

24

29

34

40

45

49

50

52

52

53

53

52

42

34

25

15

16

17

21

26

24

22

20

16

18

17

13

0

0

0

Interest expense

87

87

145

210

274

336

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from equity method investment in Galectin Sciences, LLC

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-400

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant liabilities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-524

-424

-729

0

0

0

Other income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Total other income (expense)

180

144

28

-123

-226

-298

-242

-164

-77

12

29

34

40

45

49

50

52

52

43

-10

-78

-358

-356

-312

-255

16

17

221

226

224

222

20

-124

-506

-407

-716

0

0

0

Net loss

-14,475

-13,294

-11,207

-11,175

-12,017

-13,900

-13,232

-14,888

-15,556

-16,235

-18,444

-18,562

-19,573

-21,436

-21,516

-22,877

-22,001

-20,027

-19,087

-16,718

-15,504

-15,788

-14,856

-14,880

-13,995

-12,088

-11,665

-10,812

-10,928

-9,675

-10,667

-10,006

-10,473

-10,915

-8,656

-8,282

0

0

0

Preferred stock dividends

161

263

498

757

958

1,147

1,252

1,212

1,245

1,232

1,102

911

860

741

705

850

830

868

809

879

894

943

1,017

862

894

867

887

1,002

992

976

995

1,010

1,493

1,568

1,514

1,488

0

0

0

Warrant modification (Note 9)

-

6,622

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Preferred stock accretion

-

-

-

-

-

-

-

-

-

-

-

-

-

173

228

229

229

229

229

229

228

229

230

231

231

229

229

229

229

230

229

229

229

230

724

1,260

0

0

0

Warrant modification

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

Net loss applicable to common stockholders

-14,636

-20,179

-18,327

-18,554

-19,597

-15,047

-14,484

-16,100

-16,801

-17,467

-19,548

-19,531

-20,549

-22,350

-22,449

-23,956

-23,060

-21,124

-20,125

-17,826

-16,626

-16,960

-16,103

-15,973

-23,883

-21,947

-21,544

-20,806

-12,149

-10,881

-11,891

-11,245

-12,195

-12,713

-10,894

-11,030

0

0

0

Net loss per common share — basic and diluted

-0.06

-0.30

0.05

0.06

-0.20

-0.68

0.07

0.11

0.12

-0.07

-0.13

-0.14

-0.15

-0.16

-0.16

-0.20

-0.24

-0.19

-0.26

-0.21

-0.22

-0.17

-0.17

-0.17

-0.27

-0.14

-0.22

-0.72

-0.22

-0.17

-0.19

-0.19

-0.17

-0.29

-0.19

-0.34

-0.24

-0.03

-0.05

Weighted average common shares outstanding — basic and diluted

56,956

57,045

56,631

50,301

44,975

41,224

40,921

38,227

37,284

38,299

35,165

34,692

33,928

29,732

29,282

29,023

28,827

25,894

23,793

23,731

23,062

23,092

22,051

21,983

20,270

18,193

16,988

16,236

16,079

15,982

15,822

15,710

13,010

-

12,353

11,590

-

-

-

Weighted average common shares outstanding - basic and diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11,156

58,764

53,911